Guidelines for the management of vitiligo: the European Dermatology Forum consensus

Taı̈eb, Alain; Alomar, A.; Böhm, Markus; Dell’Anna, Maria Lucia; Pase, A. De; Eleftheriadou, Viktoria; Ezzedine, Khaled; Gauthier, Yvon; Gawkrodger, David J.; Jouary, T.; Leone, Giovanni; Moretti, Silvia; Nieuweboer‐Krobotova, L.; Olsson, Mats Joakim Robert; Parsad, Davinder; Passeron, Thierry; Tanew, Adrian; Veen, Wietze van der; Geel, Nanja van; Whitton, Maxine E; Wolkerstorfer, Albert; Picardo, Mauro

doi:10.1111/j.1365-2133.2012.11197.x

Cited by 353 publications

(373 citation statements)

References 125 publications

(154 reference statements)

Supporting

Mentioning

334

Contrasting

Unclassified

Order By: Relevance

“…367 In 2013, a new European Guideline for vitiligo was published, recommending early treatment of small lesions of recent onset and childhood vitiligo with a combination of phototherapy and topical agents. 483 …”

Section: Recommended Treatment Approaches For Vitiligomentioning

confidence: 99%

“…Other clinical guidelines that have been informed by the Cochrane systematic review include patient information sites such as the NHS Choices vitiligo module 472 (which was newly developed as a result of the Cochrane review), the BAD guidelines for the management of vitiligo, 434 European guidelines for the management of vitiligo 483 and guidelines on designing and reporting vitiligo trials. 431 Although it is disappointing that the Cochrane systematic review found mainly small, inconclusive, trials covering a host of different interventions, some clinical implications can be drawn:…”

Section: Implications For Clinical Practicementioning

confidence: 99%

“…As discussed previously in this chapter (see Update of Cochrane systematic review), topical corticosteroids and NB-UVB are among the recommended first-line treatment options for vitiligo 434,483 and evidence suggests that combination treatments may be more effective than monotherapies. 367 VITILIGO WORK PROGRAMME NIHR Journals Library www.journalslibrary.nihr.ac.uk This section summarises the design of a proposed national RCT of NB-UVB light therapy and topical corticosteroids for the treatment of patients with early and limited vitiligo.…”

Section: Introductionmentioning

confidence: 99%

“…Although the only licensed treatment for the management of vitiligo in the UK is cosmetic camouflage, several treatments are recommended for use in clinical guidelines and are commonly used in clinical practice (Clinical Knowledge Summary, 490 BAD guidelines 434 and European guidelines 483 ). The most commonly used first-line treatments for vitiligo are potent or superpotent topical corticosteroids, calcineurin inhibitors and NB-UVB.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Kim

Batchelor

Bath‐Hextall

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

Programme Grants for Applied ResearchISSN 2050-4322 (Print) ISSN 2050-4330 (Online) This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full PGfAR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/pgfar. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Programme Grants for Applied Research journalReports are published in Programme Grants for Applied Research (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors. Programme Grants for Applied Research programmeThe Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-forapplied-research.htm This reportThe research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0407-10177. The contractual start date was in September 2008. The final report began editorial review in April 2014 and was accepted for publication in April 2016. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, ...

show abstract

Section: Recommended Treatment Approaches For Vitiligomentioning

confidence: 99%

Section: Implications For Clinical Practicementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Kim

Batchelor

Bath‐Hextall

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

show abstract

“…Ideally, having dedicated psychologists in dermatology would help reduce the stigma and negative perceptions of mental health and promote the importance of integrated holistic treatment. Guidelines for the management of vitiligo recommend psychological interventions, specifically cognitive behavioural therapy (CBT) [13]. Self-help based on social anxiety associated with living with vitiligo has also been shown to be effective, however further research is required [5].…”

mentioning

confidence: 99%

The Psychosocial Complications of Vitiligo

Chandler¹,

Shah²

2014

Pigmentary Disorders

View full text Add to dashboard Cite

Interventions for Vitiligo

Ezzedine

Whitton

Pinart

2016

JAMA

View full text Add to dashboard Cite

Vitiligo is chronic idiopathic disorder of skin pigmentation that plays havocs with the social livings of patients. Its major symptom is the occurrence of white patches/lesions on human skin. It affects 1-2 % of general population. A 15 years juvenile patient was affected by generalized Vitiligo with no familial history of the ailment. The patient was asked to take two table spoonful of honey per oral mixed with one cup of boiled milk of cow early in the morning daily. White de-pigmented skin was observed to be partially re-pigmented after 4 months with the reversal of disease progression.

show abstract

Guidelines for the management of vitiligo: the European Dermatology Forum consensus

Cited by 353 publications

References 125 publications

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

The Psychosocial Complications of Vitiligo

Interventions for Vitiligo

Contact Info

Product

Resources

About